INNOGEN-B(02591),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02591 INNOGEN-B

Trading 08-13 13:40:04

7.135

+0.035

+0.49%

High7.340	Low6.900	Vol2.04M
Open7.100	D1 Closing7.100	Amplitude6.20%
Mkt Cap3.26B	Tradable Cap3.00B	Total Shares457.00M
T/O14.65M	T/O Rate0.49%	Tradable Shares420.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":7.135,"timestamp":1786599453042,"preClose":7.1,"halted":0,"volume":2041800,"delay":0,"changeRate":0.004929577464788753,"floatShares":420285370,"shares":457000000,"eps":-0.9190455041235416,"marketStatus":"Trading","change":0.035,"latestTime":"08-13 13:40:04","open":7.1,"high":7.34,"low":6.9,"amount":14650763,"amplitude":0.061972,"askPrice":7.14,"askSize":7400,"bidPrice":7.135,"bidSize":2200,"shortable":3,"etf":0,"ttmEps":-0.9620894074812263,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786608600000},"marketStatusCode":2,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":7.1,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":1.067517,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591/wiki","defaultTab":"wiki","newsList":[{"id":"1166745114","title":"INNOGEN-B Maintains Stable Share Capital Structure in July 2026; Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1166745114","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166745114?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:27","pubTimestamp":1785922074,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B) filed its Monthly Return for Equity Issuer for the month ended 31 July 2026, indicating no movements in authorised, issued or treasury...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656824855","title":"Innogen Pharma's Efsubaglutide Manufacturing Sites Receive Brazil GMP Certification","url":"https://stock-news.laohu8.com/highlight/detail?id=2656824855","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656824855?lang=en_us&edition=fundamental","pubTime":"2026-08-04 13:45","pubTimestamp":1785822301,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  said two contract manufacturing sites for its Efsubaglutide Alfa injection project received good manufacturing practice  certification from Brazil's health regulator, ANVISA.The certification confirms the sites comply with Pharmaceutical Inspection Co-operation Scheme GMP standards and is expected to support commercial production capacity as well as the drug's registration and commercialization in PIC/S member countries, according to a Monday Hong Kong bourse filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EWZS","02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171803840","title":"Hong Kong Stock Movers: INNOGEN-B Surges Over 18% in Early Trading After Two Suzhou Pegloticase Alpha Injection Contract Sites Achieve PIC/S GMP Certification","url":"https://stock-news.laohu8.com/highlight/detail?id=1171803840","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171803840?lang=en_us&edition=fundamental","pubTime":"2026-08-04 09:44","pubTimestamp":1785807856,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) saw its shares climb more than 18% in early trading, though they later pared gains to trade up 10.23% at HK$7.815, with turnover reaching HK$23.282 million.Driving the move, INNOGEN...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","KCAI","BK4588","BK4585","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178875407","title":"INNOGEN-B (02591) Secures PIC/S GMP Certificates for Two Supplier Sites of Its Key Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1178875407","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178875407?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:53","pubTimestamp":1785757985,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that as of July 27, 2026, two contract manufacturing sites for its Efesogliptin alfa injection project, both owned and operated by independent third parties, have...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375774","title":"Guangzhou Innogen Pharmaceutical - Obtainment of Pic/S Gmp Certificates for Two Contract Manufacturing Sites for Efsubaglutide Alfa Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375774?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:44","pubTimestamp":1785757449,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44010R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656757753","title":"Guangzhou Innogen Says Anvisa Grants PIC/S GMP Certificates for Two Contract Sites for Ecnoglutide Alpha Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2656757753","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656757753?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:43","pubTimestamp":1785757420,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen says ANVISA grants PIC/S GMP certificates for two contract sites for ecnoglutide alpha injectionGuangzhou Innogen said two third-party contract manufacturing sites for its ecnoglutid","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL6hQ8mJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119793972","title":"INNOGEN-B (02591) Depositary Shares Valued at HK$188 Million; Shareholder Deposits 25.29 Million Shares with Citibank","url":"https://stock-news.laohu8.com/highlight/detail?id=1119793972","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119793972?lang=en_us&edition=fundamental","pubTime":"2026-07-31 08:26","pubTimestamp":1785457575,"startTime":"0","endTime":"0","summary":"Data from the Hong Kong Stock Exchange shows that on July 30, a significant position change occurred in INNOGEN-B (02591), with depositary shares valued at a total of HK$188 million, representing a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","LU0314106906.USD","BK4559","LU1244550221.USD","LU2456880835.USD","LU0203345920.USD","LU1668664300.SGD","LU2462157665.USD","LU2236285917.USD","BK4585","LU0128525689.USD","LU0130102774.USD","LU2125154778.USD","LU0052756011.USD","LU1074936037.SGD","IYF","LU0203347892.USD","LU1506573853.SGD","BK4504","LU2417539215.USD","LU0980610538.SGD","LU0106831901.USD","LU0130517989.USD","TFNS","LU1162221912.USD","LU0072461881.USD","LU2125154935.USD","BK1161","LU1791807156.HKD","BK4534","LU0310800965.SGD","LU0162691827.USD","LU0098860793.USD","LU0320765646.SGD","LU1267930227.SGD","LU0477156953.USD","FTXO","LU1244550577.SGD","LU0648001328.SGD","C","LU0170899867.USD","LU1366192091.USD","BK4207","LU1244550494.USD","IE00BSNM7G36.USD","LU1201861249.SGD","BK4566","02591","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655830996","title":"Innogen Pharma Doses First Patient in Phase 1b Trial of Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2655830996","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655830996?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:50","pubTimestamp":1785293403,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  has enrolled and dosed the first patient in the Phase 1b clinical trial of Efsubaglutide Alfa for the treatment of adolescent obesity, according to a Tuesday Hong Kong bourse filing.The company said that no safety concerns or adverse reactions were observed during the post-dosing observation period.Shares of the pharma company were up more than 2% in Wednesday morning trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168740565","title":"INNOGEN-B completes first patient dosing in Phase Ib adolescent-obesity trial for Efsubaglutide Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1168740565","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168740565?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:46","pubTimestamp":1785242819,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) reported that the first adolescent patient has been enrolled and dosed in the Phase Ib clinical trial of Efsubaglutide Alfa for obesity...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651156964","title":"Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591): Is Breakeven Near?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651156964","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651156964?lang=en_us&edition=fundamental","pubTime":"2026-07-16 11:38","pubTimestamp":1784173082,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd ( HKG:2591 ) is possibly approaching a major achievement in its...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2591/guangzhou-innogen-pharmaceutical-group-shares/news/guangzhou-innogen-pharmaceutical-group-co-ltd-hkg2591-is-bre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2591/guangzhou-innogen-pharmaceutical-group-shares/news/guangzhou-innogen-pharmaceutical-group-co-ltd-hkg2591-is-bre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101364795","title":"Assessing Supply Chain Compliance Risks for a Company with a Single Commercial Product: The INNOGEN-B Patent Infringement Case","url":"https://stock-news.laohu8.com/highlight/detail?id=1101364795","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101364795?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:21","pubTimestamp":1783664460,"startTime":"0","endTime":"0","summary":"The Beijing Intellectual Property Court has recently accepted a utility model patent infringement case filed by Suzhou Jiashu Biology against Shanghai Yinno Medicine and Beijing JD Pharmacy. While JD...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123803607","title":"INNOGEN-B Shares Surge Over 17% Following NMPA Approval for Adolescent Weight Loss Trial of Esupaglutide α","url":"https://stock-news.laohu8.com/highlight/detail?id=1123803607","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123803607?lang=en_us&edition=fundamental","pubTime":"2026-06-23 09:58","pubTimestamp":1782179905,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) are currently trading sharply higher, with gains exceeding 17%. At the time of writing, the stock is up 14.03% to HK$8.94, with a trading turnover of HK$45.71 million.The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK4588","BK4585","IND","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645040877","title":"Innogen Pharmaceutical CEO addresses DIA Global Annual Meeting 2026 China Town Hall","url":"https://stock-news.laohu8.com/highlight/detail?id=2645040877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645040877?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:40","pubTimestamp":1782117613,"startTime":"0","endTime":"0","summary":"Innogen joined the DIA Global Annual Meeting 2026 China Town Hall session in Philadelphia.CEO Qinghua Wang outlined efsubaglutide alfa’s China approval for type 2 diabetes, citing ongoing obesity Phase 2 in Australia, diabetes bridging study in Brazil.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL147jTz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044484","title":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044484","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645044484?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:36","pubTimestamp":1782113804,"startTime":"0","endTime":"0","summary":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK climb 4.4% to HK$7.87, on course for the biggest one-day pct gain since May 19** Hong Kong-listed pharmaceutical products developer says it has received approval from China's National Medical Products Administration to commence Phase Ib clinical trials for its Efsubaglutide Alfa for the treatment of obesity in adolescents** Company expects to commence clinical trial in July 2026 and plans to enroll about 36 participants for the clinical trial** YTD, stock down 74.6%, Hang Seng Biotech Index .HSBIO donw 15.7%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL1N42U07V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645497610","title":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645497610","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645497610?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:48","pubTimestamp":1782110893,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial June 22  - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO - ON 17 JUNE, RECEIVES CHINA APPROVAL TO START PHASE IB TRIAL FOR EFSUBAGLUTIDE ALFA IN ADOLESCENT OBESITYFurther company coverage: 2591.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645049125","title":"Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2645049125","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645049125?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:38","pubTimestamp":1782110339,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  obtained approval to conduct phase Ib clinical trials for Efsubaglutide Alfa from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is being tested for the treatment of obesity in adolescents.The company expects to begin the trial in July and enroll around 36 participants.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183559762","title":"INNOGEN-B Receives NMPA Clearance for Phase Ib Trial of Esupaglutide Alpha in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=1183559762","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183559762?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:49","pubTimestamp":1782103749,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) has announced that it received approval from China's National Medical Products Administration (NMPA) on June 17, 2026, to initiate a Phase Ib clinical trial for its drug candidate,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645704354","title":"Guangzhou Innogen Pharmaceutical Group Co - on 17 June, Receives China Approval to Start Phase Ib Trial for Efsubaglutide Alfa in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2645704354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645704354?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:07","pubTimestamp":1782101278,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185876958","title":"Innogen Pharmaceutical Sets 29 June 2026 AGM; Seeks to Scrap Supervisory Committee and Launch Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1185876958","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185876958?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:05","pubTimestamp":1780661110,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“Innogen Pharmaceutical”), stock name INNOGEN-B, has issued a proxy circular outlining 24 resolutions to be tabled at its annual general meeting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155251925","title":"INNOGEN-B AGM Agenda: Share Award Scheme, 20% Issue Mandate, Supervisory Committee Abolition","url":"https://stock-news.laohu8.com/highlight/detail?id=1155251925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155251925?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:26","pubTimestamp":1780658769,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) has published a circular for its Annual General Meeting (AGM) scheduled on 29 June 2026 in Shanghai, detailing 17 resolutions for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":-0.036},{"period":"1month","weight":-0.1394},{"period":"3month","weight":-0.4799},{"period":"6month","weight":-0.7428},{"period":"1year","weight":-0.6199},{"period":"ytd","weight":-0.7683}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The Company is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The Company principally conducts its businesses in the domestic market.","exchange":"SEHK","name":"INNOGEN-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOGEN-B(02591),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOGEN-B(02591) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOGEN-B,02591,INNOGEN-B股票,INNOGEN-B股票老虎,INNOGEN-B股票老虎国际,INNOGEN-B行情,INNOGEN-B股票行情,INNOGEN-B股价,INNOGEN-B股市,INNOGEN-B股票价格,INNOGEN-B股票交易,INNOGEN-B股票购买,INNOGEN-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOGEN-B(02591),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOGEN-B(02591) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}